Effect of Intratumoral Injection of Carboplatin Combined with Pluronic P85 or L61 on Experimental Colorectal Carcinoma in Rats

Abstract

Pluronic, a poly(ethylene oxide)-poly(propylene oxide)-poly (ethylene oxide) block copolymer, has been shown to enhance the cytotoxic activity of anticancer drugs in various cell lines. In the current study the effect of Pluronic P85 (P85) and Pluronic L61 (L61) on the intratumoral chemotherapy of an experimental adenocarcinoma in rats was examined. A total of 120 subcutaneous tumors (4 per rat) were inoculated in 30 BDIX rats and were treated weekly for 4 weeks with intratumoral injection of carboplatin (CPt) alone or with either P85 or L61. Tumors were monitored weekly and were excised at the endpoint for histologic evaluation. The effect of Pluronic on levels of intracellular ATP was explored as a possible mechanism of sensitization. Results showed that tumors treated with low-dose CPt (2.8 mg/kg) and P85 or L61 exhibited significant reductions in tumor volume after 28 days relative to Day 0 (112.7% ± 34.4%, n = 15; 131.3% ± 55.6%, n = 8) compared with tumors treated with free drug (339.4% ± 75.0%, n = 16). Control tumors treated with either P85 or L61 alone or with saline showed volume increases of 1079.4% ± 143.6% (n = 16), 729.4% ± 202.2% (n = 7), and 1119.2% ± 6.1% (n = 16), respectively. Treatment with high-dose CPt (20.7 mg/kg) led to a 79.3% ± 4.2% reduction in tumor volume, and no differences were noted with addition of P85 or L61. In vitro ATP measurements showed that 28.0 mg/kg of P85 significantly reduced levels of intracellular ATP to 44.7% ± 1.5% of controls, whereas L61 at this concentration depleted ATP levels completely. Results confirm that Pluronic P85 and L61 act as potent sensitizers to carboplatin chemotherapy of the experimental colorectal carcinoma, leading to a significant reduction of tumor growth compared to carboplatin alone. ATP depletion is a possible mechanism for these observed differences.

Get full access to this article

View all access options for this article.

References

Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317–325, 2002.

Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161–183, 1997.

Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 10:1663–1682, 2003.

Daubeuf S, Balin D, Leroy P, Visvikis A. Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol 66:595–604, 2003.

Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82:189–212, 2002.

Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54:759–779, 2002.

Batrakova EV, Li S, Alakhov VY, Elmquist WF, Miller DW, Kabanov AV. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res 20:1581–1590, 2003.

Minko T, Batrakova EV, Li S, Li Y, Pakunlu RI, Alakhov VY, Kabanov AV. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 105:269–278, 2005.

Alakhov V, Moskaleva E, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 7:209–216, 1996.

10.

Exner AA, Krupka TM, Scherrer K, Teets JM. Enhancement of carboplatin toxicity by Pluronic block copolymers. J Control Release 106:188–197, 2005.

11.

Krupka TM, Weinberg BD, Ziats NP, Haaga JR, Exner AA. Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Invest Radiol 41:890–897, 2006.

12.

Batrakova E, Lee S, Li S, Venne A, Alakhov V, Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 16:1373–1379, 1999.

13.

Miller DW, Batrakova EV, Kabanov AV. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 16:396–401, 1999.

14.

Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br J Cancer 85:1987–1997, 2001.

15.

Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 299:483–493, 2001.

16.

Zhirnov AE, Demina TV, Krylova OO, Grozdova ID, Melik-Nubarov NS. Lipid composition determines interaction of liposome membranes with Pluronic L61. Biochim Biophys Acta 1720:73–83, 2005.

17.

Melik-Nubarov NS, Pomaz OO, Dorodnych T, Badun GA, Ksenofontov AL, Schemchukova OB, Arzhakov SA. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers. FEBS Lett 446:194–198, 1999.

18.

Krylova OO, Melik-Nubarov NS, Badun GA, Ksenofontov AL, Menger FM, Yaroslavov AA. Pluronic L61 accelerates flip-flop and transbilayer doxorubicin permeation. Chemistry 9:3930–3936, 2003.

19.

Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:162–190, 1989.

20.

Woloschuk DM, Pruemer JM, Cluxton RJ Jr. Carboplatin: a new cisplatin analog. Drug Intell Clin Pharm 22:843–849, 1988.

21.

Lelieveld P, Van der Vijgh WJ, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20:1087–1104, 1984.

22.

Boven E, van der Vijgh WJ, Nauta MM, Schluper HM, Pinedo HM. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45:86–90, 1985.

23.

Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12(Suppl A):125–136, 1985.

24.

Goren MP, Forastiere AA, Wright RK, Horowitz ME, Dodge RK, Kamen BA, Viar MJ, Pratt CB. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 19:57–60, 1987.

25.

Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36:1925–1932, 1987.

26.

Schem BC, Mella O, Dahl O. Thermochemotherapy with cisplatin or carboplatin in the BT4 rat glioma in vitro and in vivo. Int J Radiat Oncol Biol Phys 23:109–114, 1992.

27.

Nelson JL, Roeder BL, Carmen JC, Roloff F, Pitt WG. Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res 62:7280–7283, 2002.

28.

Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626–3629, 1996.

29.

Chen YC, Liang HD, Zhang QP, Blomley MJ, Lu QL. Pluronic block copolymers: novel functions in ultrasound-mediated gene transfer and against cell damage. Ultrasound Med Biol 32:131–137, 2006.

30.

Mortensen K. PEO-related block copolymer surfactants. Colloids and Surfaces A: Physicochem Eng Aspects 183–185:277–292, 2001.

31.

Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19:1–72, 2002.